AmerisourceBergen Announces Date and Time for Fourth Quarter Fiscal 2017 Earnings Release
October 05 2017 - 8:00AM
Business Wire
AmerisourceBergen Corporation (NYSE: ABC) today announced that
it plans to release its results for the Fourth Quarter Fiscal 2017
on Thursday, November 2, 2017 prior to the opening of trading on
the New York Stock Exchange. The Company will host a conference
call to discuss the results at 8:30 a.m. ET on November 2,
2017.
Participating in the conference call will be:
Steven H. Collis, Chairman, President &
Chief Executive OfficerTim G. Guttman, Executive Vice President
& Chief Financial Officer
The dial-in number for the live call will be (612) 234-9959. No
access code is required. The live call will also be webcast via the
Company’s website at www.amerisourcebergen.com. Users are
encouraged to log on to the webcast approximately 10 minutes in
advance of the scheduled start time of the call.
Replays of the call will be made available via telephone and
webcast. A replay of the webcast will be posted on
www.amerisourcebergen.com approximately two hours after the
completion of the call and will remain available for 30 days. The
telephone replay will also be available approximately two hours
after the completion of the call and will remain available for
seven days. To access the telephone replay from within the U.S.,
dial (800) 475-6701. From outside the U.S., dial (320) 365-3844.
The access code for the replay is 430974.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products,
value-driving services and business solutions that improve access
to care. Tens of thousands of healthcare providers, veterinary
practices and livestock producers trust us as their partner in the
pharmaceutical supply chain. Global manufacturers depend on us for
services that drive commercial success for their products. Through
our daily work—and powered by our 20,000 associates—we are united
in our responsibility to create healthier
futures. AmerisourceBergen is ranked #11 on the Fortune
500, with more than $145 billion in annual revenue. The
company is headquartered in Valley Forge, Pa. and has a
presence in 50+ countries. Learn more at amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Words such as "expect," "likely," "outlook,"
"forecast," "would," "could," "should," "can," "will," "project,"
"intend," "plan," "continue," "sustain," "synergy," "on track,"
"believe," "seek," "estimate," "anticipate," "may," "possible,"
"assume," variations of such words, and similar expressions are
intended to identify such forward-looking statements. These
statements are based on management's current expectations and are
subject to uncertainty and change in circumstances. These
statements are not guarantees of future performance and are based
on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors
that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: unfavorable
trends in brand and generic pharmaceutical pricing, including in
rate or frequency of price inflation or deflation; competition and
industry consolidation of both customers and suppliers resulting in
increasing pressure to reduce prices for our products and services;
changes in pharmaceutical market growth rates; substantial defaults
in payment, material reduction in purchases by or the loss,
bankruptcy or insolvency of a major customer; changes to the
customer or supplier mix; the retention of key customer or supplier
relationships under less favorable economics or the adverse
resolution of any contract or other dispute with customers or
suppliers; changes to customer or supplier payment terms; the
disruption of the Company's cash flow and ability to return value
to its stockholders in accordance with its past practices; risks
associated with the strategic, long-term relationship between
Walgreens Boots Alliance, Inc. and the Company, including with
respect to the pharmaceutical distribution agreement and/or the
global sourcing arrangement; changes in the United States
healthcare and regulatory environment, including changes that could
impact prescription drug reimbursement under Medicare and Medicaid;
increasing governmental regulations regarding the pharmaceutical
supply channel and pharmaceutical compounding; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; prosecution or suit by federal, state and other
governmental entities of alleged violations of laws and regulations
regarding controlled substances, and any related disputes,
including shareholder derivative lawsuits; increased federal
scrutiny and litigation, including qui tam litigation, for alleged
violations of laws and regulations governing the marketing, sale,
purchase and/or dispensing of pharmaceutical products or services,
and associated reserves and costs; material adverse resolution of
pending legal proceedings; declining reimbursement rates for
pharmaceuticals; the acquisition of businesses that do not perform
as expected, or that are difficult to integrate or control,
including the integration of PharMEDium, or the inability to
capture all of the anticipated synergies related thereto;
regulatory action in connection with the production, labeling or
packaging of products compounded by our compounded sterile
preparations (CSP) business; declining economic conditions in the
United States and abroad; financial market volatility and
disruption; the loss, bankruptcy or insolvency of a major supplier;
interest rate and foreign currency exchange rate fluctuations;
managing foreign expansion, including non-compliance with the U.S.
Foreign Corrupt Practices Act, anti-bribery laws and economic
sanctions and import laws and regulations; malfunction, failure or
breach of sophisticated information systems to operate as designed;
risks generally associated with data privacy regulation and the
international transfer of personal data; changes in tax laws or
legislative initiatives that could adversely affect the Company's
tax positions and/or the Company's tax liabilities or adverse
resolution of challenges to the Company's tax positions; natural
disasters or other unexpected events that affect the Company’s
operations; the impairment of goodwill or other intangible assets,
resulting in a charge to earnings; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors
affecting the Company's business generally. Certain additional
factors that management believes could cause actual outcomes and
results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk
Factors) in the Company’s Annual Report on Form 10-K for the fiscal
year ended September 30, 2016 and elsewhere in that
report and (ii) in other reports filed by the Company pursuant to
the Securities Exchange Act.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171005005241/en/
AmerisourceBergen CorporationKeri P. Mattox,
610-576-7801Vice President, Corporate & Investor
Relationskmattox@amerisourcebergen.comorBennett
S. Murphy, 610-727-3693Director, Corporate & Investor
Relationsbmurphy@amerisourcebergen.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Sep 2023 to Sep 2024